Your Partner. For science. For life.

Battling chronic ailments. Evolving science. Improving quality of life. Even helping people get a better night’s sleep. Our portfolio companies are positively impacting the world every day with their visionary people and life-changing products.

What they do.

Developing a late-stage drug to help chronic liver disease patients with low blood platelet counts.

Status:

The program is currently in two global Phase 3 trials.

Achievement of note:

Dova has raised capital from several highly respected investment firms including Perceptive Advisors, Paulson Capital and several significant family offices.

How they’re improving the quality of people’s lives:

Avatrombopag, if approved, would be a first-in-class drug, allowing those with chronic liver disease and low platelet counts to have procedures performed without the risks associated with transfusions. In many cases, patients within this population may have developed refractoriness to transfusions, and therefore have no approved alternatives to prepare their body for necessary procedures.